Atropine Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MA
Published August 21, 2013 · Recall initiated: March 25, 2013
Summary
FDA records drug Class II recall D-859-2013, published August 21, 2013 and initiated March 25, 2013. Recalling firm: Pallimed Solutions; Status: Terminated; Lot: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Pallimed Solutions
- Distributor
- Nationwide
- Lot
- All lots within expiry
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAVancomycin Ophthalmic PF, compounded by Pallimed Solutions Pharmacy, Wobrun, MAAugust 21, 2013
- FDAAlprostadil IN NS Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDAGentamicin Sulfate Irrigation, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDAHCG Chorionic Gonadotropin, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDABacteriostatic Water for Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDAAcetylcysteine Ophthalmic Solution, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
Questions about this recall
Was Atropine Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MA recalled?
Yes. FDA published recall D-859-2013 on August 21, 2013. Reported hazard: Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit